Meeker JR, Price AM, Martin E, Vaughn I, Wernli KJ. Influenza B Circulation and Vaccine Effectiveness Against Medically Attended Outpatient Influenza B Illness, United States, 2016-17 Through 2024-25. J Infect Dis. 2026 Oct 31:jiag538
Background: Influenza B vaccine effectiveness (VE) has varied by season, lineage, antigenic drift, and vaccine composition. After B/Yamagata detection ceased globally, trivalent vaccines containing B/Victoria were reintroduced in 2024-25. We evaluated influenza B circulation and VE across eight analyzed seasons spanning this transition.
Methods: Ambulatory patients aged ≥6 months with acute respiratory illness were enrolled at U.S. Flu VE Network sites during eight influenza seasons from 2016-17 through 2024-25; 2020-21 was excluded because influenza circulation was negligible. Participants were tested by RT-PCR. Lineage-specific VE was estimated using a test-negative design and logistic regression adjusted for age, sex, race/ethnicity, calendar time, and study site. VE was reported for season-lineage strata with ≥50 influenza B cases.
Results: Among 65,773 participants, 3,629 influenza B cases were included in lineage-specific VE analyses (1,507 B/Yamagata; 2,122 B/Victoria). Six of 10 season-lineage strata met the reporting threshold. B/Victoria VE was 58% (95% CI, 28%-77%) in 2016-17, 51% (43%-57%) in 2019-20, 78% (71%-84%) in 2023-24, and 39% (14%-56%) in 2024-25. B/Yamagata VE was 55% (46%-63%) in 2016-17 and 49% (40%-56%) in 2017-18.
Conclusions: Influenza vaccines protected against medically attended outpatient influenza B illness, although VE varied by season. Continued VE monitoring and genetic surveillance are needed to detect emerging influenza B viruses and inform vaccine strain selection.
Methods: Ambulatory patients aged ≥6 months with acute respiratory illness were enrolled at U.S. Flu VE Network sites during eight influenza seasons from 2016-17 through 2024-25; 2020-21 was excluded because influenza circulation was negligible. Participants were tested by RT-PCR. Lineage-specific VE was estimated using a test-negative design and logistic regression adjusted for age, sex, race/ethnicity, calendar time, and study site. VE was reported for season-lineage strata with ≥50 influenza B cases.
Results: Among 65,773 participants, 3,629 influenza B cases were included in lineage-specific VE analyses (1,507 B/Yamagata; 2,122 B/Victoria). Six of 10 season-lineage strata met the reporting threshold. B/Victoria VE was 58% (95% CI, 28%-77%) in 2016-17, 51% (43%-57%) in 2019-20, 78% (71%-84%) in 2023-24, and 39% (14%-56%) in 2024-25. B/Yamagata VE was 55% (46%-63%) in 2016-17 and 49% (40%-56%) in 2017-18.
Conclusions: Influenza vaccines protected against medically attended outpatient influenza B illness, although VE varied by season. Continued VE monitoring and genetic surveillance are needed to detect emerging influenza B viruses and inform vaccine strain selection.
See Also:
Latest articles in those days:
- Weekly US Influenza Surveillance Report: Key Updates for Week 45, ending November 14, 2026 11 hours ago
- Anatomical Compartmentalization in Chickens Drives Divergent H9N2 Influenza Evolution Toward Human Receptor Binding and Immune Escape 1 days ago
- Epidemiologic Variability and Clinical Severity Across 11 Influenza Seasons in Children 2 days ago
- Molecular Epidemiology of Clade 2.3.4.4b H5N1 High-Pathogenicity Avian Influenza in South Africa, 2025-2026 2 days ago
- Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin 2 days ago
[Go Top] [Close Window]


